• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Topic: MS

What is the optimal dosing of natalizumab?

July 25, 2012  

Breastfeeding not a sustainable therapy

July 11, 2012  

High cost of MS in Canada

May 16, 2012  

IFN-beta in CIS: phase III REFLEX results

May 2, 2012  

Oral anti-alpha4-integrin in development

March 14, 2012  

Alemtuzumab: high rate of autoimmune disorders

December 14, 2011  

Emerging MS therapies: update on injectable drugs

November 30, 2011  

CONFIRM – Second phase III trial results for BG-12

November 30, 2011  

No benefit with simvastatin add-on therapy in MS

November 9, 2011  

Laquinimod: Few cheers for BRAVO results

September 21, 2011  
Previous
33
34
35
36
37
Next

Browse by Topic

  • MS (414)
  • CLINICAL CASES IN MS (16)
  • EPILEPSY (36)
  • AAN 2025 (5)
  • BIOMARKERS IN MS (54)
  • ACTRIMS 2025 (6)
  • Library (17)
  • AES 2024 (1)
  • ECTRIMS 2024 (6)
  • EAN 2024 (3)
  • AD (85)
  • AAN 2024 (5)
  • ACTRIMS Forum 2024 (2)
  • PD (77)
  • COVID-19 (58)
  • MIGRAINE (25)
  • DEPRESSION (36)
  • STROKE (22)
  • SCHIZOPHRENIA (25)
  • DEMENTIA (10)
  • SLEEP (2)
  • PAIN (3)
  • BPD (4)
  • ALS (1)

Popular Posts

  • DMT prescribing in Canada – survey results posted on June 6, 2025
  • Proton pump inhibitors linked to neurological conditions posted on November 29, 2019
  • CLINICAL CASES IN MS: A 42 Y.O. WOMAN WITH A SEVERE RELAPSE ON DMF posted on June 2, 2025
Copyright 2025 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions